XHKG
9933
Market cap184mUSD
May 14, Last price
1.54HKD
1D
6.29%
1Q
-20.00%
IPO
353.73%
Name
GHW International
Chart & Performance
P/E
105.32
P/S
0.35
EPS
0.01
Div Yield, %
—
Shrs. gr., 5y
4.71%
Rev. gr., 5y
14.46%
Revenues
3.86b
+20.02%
Net income
13m
+368.17%
CFO
0k
-100.00%
Profile
GHW International, an investment holding company, manufactures and sells chemical and pharmaceutical products in the People's Republic of China, Europe, Vietnam, rest of Asia, and internationally. It operates through four segments: Polyurethane Materials, Animal Nutrition Chemicals, Fine Chemicals, and Pharmaceutical Products and Intermediates. The Polyurethane Materials segment offers polymeric methylene diphenyl diisocyanate and toluene diisocyanate, and polymer polyether for use in cushion foams, interior components, and other lightweight automotive parts. The Animal Nutrition Chemicals segment provides choline chloride and betaine used in feeds for poultry and livestock. The Fine Chemicals segment offers carboxylic acids, solvents, resins, and oleochemicals used in the paint and synthesis of dyes, production of lubricants, emulsifiers, cosmetics, flavors and fragrances, and feed additives. The Pharmaceutical Products and Intermediates segment produces and sells isooctanoic acid and diethyl sulfate for use in paint drier, fungicide, preservative and pharmaceutical raw materials, synthesis of dyes, pesticides, and pharmaceutical intermediates; and iodine and iodine derivatives, and pharmaceutical products, such as cefpodoxime dispersible tablets. GHW International was founded in 1995 and is headquartered in Nanjing, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | 3,861,966 20.02% | 3,217,669 -4.77% | 3,378,707 19.25% | ||||||
Cost of revenue | 3,830,169 | 3,212,253 | 3,054,447 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 31,797 | 5,416 | 324,260 | ||||||
NOPBT Margin | 0.82% | 0.17% | 9.60% | ||||||
Operating Taxes | 339 | (9,510) | 33,401 | ||||||
Tax Rate | 1.07% | 10.30% | |||||||
NOPAT | 31,458 | 14,926 | 290,859 | ||||||
Net income | 12,753 368.17% | 2,724 -99.01% | 274,627 110.10% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (23,021) | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 709,577 | 476,683 | 400,557 | ||||||
Long-term debt | 162,927 | 248,302 | 267,756 | ||||||
Deferred revenue | 227,371 | ||||||||
Other long-term liabilities | 23,064 | 34,827 | (260,183) | ||||||
Net debt | 769,025 | 647,144 | 575,011 | ||||||
| Cash flow | |||||||||
Cash from operating activities | 120,070 | 234,079 | |||||||
CAPEX | (139,878) | (274,365) | |||||||
Cash from investing activities | (140,433) | (197,720) | |||||||
Cash from financing activities | (4,970) | 9,071 | |||||||
FCF | (95,619) | (57,352) | 94,079 | ||||||
| Balance | |||||||||
Cash | 101,735 | 77,841 | 103,296 | ||||||
Long term investments | 1,744 | (9,994) | |||||||
Excess cash | |||||||||
Stockholders' equity | 621,576 | 526,219 | 524,401 | ||||||
Invested Capital | 1,506,992 | 1,334,565 | 1,260,605 | ||||||
ROIC | 2.21% | 1.15% | 25.44% | ||||||
ROCE | 2.11% | 0.41% | 25.07% | ||||||
| EV | |||||||||
Common stock shares outstanding | 943,975 | 974,759 | 1,000,000 | ||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | 31,797 | 19,291 | 335,993 | ||||||
EV/EBITDA | |||||||||
Interest | 39,207 | 36,988 | |||||||
Interest/NOPBT | 723.91% | 11.41% | |||||||